证券代码：000813 证券简称：德展健康 公告编号：2025-065 德展大健康股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 德展大健康股份有限公司（以下简称"公司""德展健康"）第八届董事会 第三十四次会议的通知已于 2025 年 8 月 21 日以电子邮件方式发出；公司于 2025 年 8 月 26 日 10:30 以现场结合通讯表决方式在公司北京办公区会议室召开。本 次会议应参加会议董事 9 人，实际参加会议董事 9 人。会议由董事长魏哲明先生 主持，全部高管列席了本次会议。本次会议的召集、召开符合《公司法》及《公 司章程》的规定。 二、董事会会议审议情况 （一）关于修订《公司章程》的议案 根据公司 2024 年第一次临时股东大会审议通过的《关于回购公司股份方案 的议案》，公司回购方案已实施完毕，累计回购股份数量 67,850,450 股。截至 目前，公司已完成上述回购股份的注销事项，根据《上市公司章程指引》的有关 规定，公司拟对《公司章程》相关条款进行修订。 该议案审议获得通过，尚需提交公司股东会审议。 具体内 ...

Group 1 - The board of directors of Guangdong Jushi Chemical Co., Ltd. held its second meeting of the seventh session on August 18, 2025, with all 9 directors present, ensuring compliance with relevant laws and regulations [1][2][3] - The board approved the proposal to use remaining raised funds totaling 43.5838 million RMB for permanent working capital, which accounts for 15.28% of the total raised funds [1][2] - The board also approved a special report on the use of previously raised funds, which was verified by Zhongxinghua Accounting Firm [2] - A proposal for the third extraordinary shareholders' meeting scheduled for September 3, 2025, was also approved [2][3]

Group 1 - The company held its 20th meeting of the 11th Board of Directors on August 8, 2025, with all 7 directors present, and the meeting complied with relevant regulations [1][2] - The board approved the nomination of Mr. Liu Dahong as an independent director candidate, with a unanimous vote of 7 in favor [1][2] - The current independent director, Ms. Ni Jieyun, will not continue after her term ends, as she has served for the maximum allowed six years [1][2] Group 2 - The board also approved the expansion of the company's business scope and amendments to the Articles of Association, which will require shareholder approval [2] - A resolution was passed to convene the company's second extraordinary general meeting of 2025, with all 7 directors voting in favor [3]

Group 1 - The company held its 23rd meeting of the 3rd Board of Directors on July 16, 2025, with all 9 directors present [1][2] - The board approved the nomination of candidates for the 4th Board of Directors, including 5 non-independent directors, with a term of three years starting from the first extraordinary shareholders' meeting in 2025 [1][2] - The board also approved the nomination of 3 independent director candidates, with the same term conditions as the non-independent directors [2][3] Group 2 - The board confirmed that the current non-independent directors will continue to fulfill their duties until the new board is in place [2][3] - The board approved amendments to the company's articles of association to comply with the latest regulations and improve governance [4][5] - The board proposed to hold the first extraordinary shareholders' meeting on August 5, 2025, to vote on the nominations and other matters [6]

证券代码：002424 证券简称：ST百灵 公告编号：2025-027 贵州百灵企业集团制药股份有限公司 本公司及董事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 一、会议召开情况 六届董事会第十七次会议由公司董事长姜伟先生召集，会议通知于 现场结合通讯方式召开。 其中独立董事胡坚、晏国菀、杨明、张洪武以通讯方式进行表决。 员列席了本次董事会。 议案二、审议通过《关于公司为控股子公司安顺市大健康医药产 业运营有限公司申请贷款提供担保的议案》； 公司控股子公司安顺市大健康医药产业运营有限公司拟向贵州 银行股份有限公司安顺分行申请续贷款14,800万元，期限为2年，公 司将继续按持股比例55%提供连带责任担保8,140万元，大健康医药另 一股东安顺市医投科技服务有限公司将按持股比例45%提供连带责任 担保6,660万元。 会议事规则》及相关法规的规定。 二、会议审议情况 经现场及通讯投票表决，会议审议通过了以下议案： 议案一、审议通过《关于申请撤销其他风险警示的议案》； 具体内容详见公司在指定信息披露媒体巨潮资讯网 （www.cninfo.com.cn）、《证券时报》《证 ...